Abbreviations & Acronyms AR-V7 = androgen receptor splice variant 7 BCa = bladder cancer CRPC = castration-resistant prostate cancer Dex = dendritic cell derived extracellular vesicles EDIL-3 = epidermal growth factor-like repeats and discoidin I-like domain-3 EV = extracellular vesicle HUVEC = human umbilical vein endothelial cells lncARSR = long non-coding ribonucleic acid activated in renal cell carcinoma with sunitinib resistance lncRNA = long non-coding ribonucleic acid miRNA = micro ribonucleic acid mRNA = messenger ribonucleic acid MVB = multivesiclular body nSMase2 = neutral sphingomyelinase 2 PCa = prostate cancer PD-1 = programmed death 1 PD-L1 = programmed death 1 ligand 1 RCC = renal cell carcinoma siRNA = small interfering ribonucleic acid TACSTD2 = tumor-associated calcium-signal transducer 2 Abstract: Extracellular vesicles are nanometer-sized lipid membranous vesicles that are released from almost all types of cells into the extracellular space. Extracellular vesicles have gained considerable attention in the past decade, and emerging evidence suggests that they play novel roles in mediating cancer biology. Extracellular vesicles contain pathogenic components, such as proteins, DNA fragments, messenger ribonucleic acids, non-coding ribonucleic acids and lipids, all of which mediate paracrine signaling in the tumor microenvironment. Extracellular vesicles impact the multistep process of cancer progression through modulation of the immune system, angiogenesis and pre-metastatic niche formation through transfer of their contents. Therefore, a better understanding of their roles in urological cancers will provide opportunities for novel therapeutic strategies. In addition, the contents of extracellular vesicles hold promise for the discovery of liquid-based biomarkers for prostate, kidney and bladder cancers. Here, we summarize the current research regarding extracellular vesicles in urological cancer and discuss potential clinical applications for extracellular vesicles in urological cancer.
Introduction
EVs consist of a wide variety of small membrane-bound vesicles, including exosomes and microvesicles, which are actively released from almost all types of cells. 1 Initially, it was shown that the release of EVs was part of a disposal process to discard unwanted materials from cells. 2 In 2007, Jan L€ otvall's group showed that variable RNA, such as miRNA and mRNA, can be transferred between cells through EVs. 3 In 2010, three research groups reported that these transferred miRNAs were able to function within the recipient cells. [4] [5] [6] Since then, emerging evidence has shown that EVs are important mediators of extracellular signaling pathways through transfer of their cargo. Depending on the cell origin, EV content varies greatly. EVs transfer functional molecules, including miRNAs, mRNAs, proteins, DNA fragments and lipids, into recipient cells. Through the transfer of these contents, EVs have been reported not only to function in normal physiological processes, 7 but also to be associated with the pathogenesis of various diseases, including cancer. 8, 9 Accumulating evidence shows that EVs play decisive roles in tumorigenesis, growth, progression, metastasis and drug resistance. 10 In addition, EVs reflect the phenotypes of parental cells, and many reports have shown their usefulness as diagnostic or prognostic biomarkers. 11 Furthermore, the concept of using EVs for siRNA delivery based on the discovery of miRNA transfer is also an important aspect of EV research. 12 In the present review, we provide a brief introduction to EVs, summarize the current knowledge on EVs in the urological cancer field and discuss potential clinical applications for the near future.
the formation of MVBs. The MVBs fuse with the cellular membrane to release exosomes into the extracellular milieu. 15 These processes are regulated by several factors, such as Rab proteins, lipid ceramide and endosomal sorting complexes required for transport. As exosomal markers, terraspanins (CD9, CD63 and CD81), heat shock proteins (HSP60, 70 and 90) , membrane transporters, fusion proteins (annexins and flotillin) and MVB synthesis proteins (Alix and TSG101) have been reported. 16, 17 Microvesicles are 100-1000 nm in diameter and are directly shed from the plasma membrane under physiological conditions or in response to stimuli. 18 Microvesicles are enriched in some lipids, such as cholesterol and phosphatidylserine, the latter of which is relocated to the outer membrane leaflet, specifically at the site of microvesicle shedding. 19 Apoptotic bodies are 500-4000 nm in diameter and are formed when the cell undergoes programmed cell death. They contain fragmented nuclei, as well as fragmented cytoplasmic organelles, which influence the cellular response by transferring their contents to recipient cells (Fig. 1) . 20 In addition, prostasomes are popular EVs in the field of urology. Prostasomes are 40-500 nm in diameter and contain a cholesterol-rich multilayered lipid membrane. 21 Prostasomes are secreted from prostate epithelial cells and are present in high concentrations in seminal fluid. 22 Interestingly, one of the first studies reporting a functional interaction for EVs within cells described the promotion of spermatozoa mobility by prostasomes. 23 Prostasomes also protect spermatozoa from infection and phagocytosis by female immune cells, thereby contributing to human reproduction. 24, 25 Furthermore, PCa cells have been shown to release prostasomes. 26 reagents, can facilitate the sedimentation of EVs. However, these are relatively rough isolation methods that contain soluble proteins. 27 A density gradient-based isolation provides the highest purification of each EV fraction, but the procedure is costly and technically complicated. 28 As there is no way to completely distinguish between each type of EV after secretion, care should be taken during the naming of each type of EV. 27 Thus, in the present review, the term EV is used as an umbrella term for all types of vesicles in the extracellular space according to the recommendation of the International Society for Extracellular Vesicles. 29 
EV isolation methods

How to use EVs as cancer treatment
Until now, a number of studies have shown the potential of EVs as therapeutic cancer tools, and these strategies are primarily divided into four ideas. Before introducing the current EV research in urological cancer treatment, general ideas for the clinical application of EV-based cancer treatment will be provided.
As therapeutic targets
Intercellular communication through EVs contributes to cancer progression in various phases. Kosaka et al. reported competition between cancer cells and the surrounding normal epithelial cells through EVs during tumor initiation. 30 A growing body of literature has shown that EVs modulate cancer progression, such as initiation of a premetastatic niche, 31, 32 induction of angiogenesis, 33 destruction of the blood-brain barrier 34 or peritoneum, 35 activation of cancerassociated fibroblasts 36 and induction of drug resistance. 37 In addition, Ono et al. reported that EVs derived from bone marrow mesenchymal stem cells induce breast cancer cells into a dormant state and contribute to future recurrence. 38 Clearly, EVs have pivotal roles in cancer progression during various phases, and therefore, reducing cancer-derived EV transfer could be a novel strategy to treat cancer patients. Three potential therapeutic strategies have been proposed: inhibition of the production of EVs, elimination of circulating EVs and disruption of EV absorption. 39 Further studies are required to put these strategies into clinical application, but some interesting findings about these strategies have already been reported. Kosaka et al. showed that the decreased activity of nSMase2, which triggers the secretion of EVs, resulted in the reduced secretion of miRNAs in EVs and inhibited lung metastasis. 33 Nishida-Aoki et al. reported that administration of human-specific CD9 and CD63 antibodies, which are enriched on the surface of EVs, decreased metastasis in a breast cancer xenograft model. 40 These studies hinted at the possibility of EV-targeted therapy as a standard strategy for cancer treatment in the future.
As biomarkers
Compared with conventional tissue biopsy, EV-based liquid biopsy has some advantages. First, EVs are found in almost all types of body fluid, such as blood, 41 urine, 42 breast milk, 43 broncho-alveolar fluid, 44 saliva 45 and semen. 25 Because of the non-invasive nature of sample collection and easy accessibility, EVs are preferred for serial collection. In some clinical situations, direct tissue biopsies do not always reflect the total tumor condition because of tumor heterogeneity. EVs are secreted from heterogeneous cancer cells and therefore provide us with the chance to monitor crucial molecular information about the current state of cancer. As aforementioned, EVs contain nucleic acids, proteins and lipids. Among these contents, RNAs and proteins have been the focus of research as cancer biomarkers. The stability of circulating RNAs has previously been questioned due to RNase in body fluids. 46 One of the causes of their stability might be their encapsulation in EVs. Until now, many reports have shown that EV-associated RNAs can be utilized for highly reproducible diagnostic approaches. 10 In addition, EV-associated proteins are also effective diagnostic molecules. EVs carry various types of proteins, such as membrane and cytosolic proteins. 11 Recently, several studies have focused on membrane proteins, which can be captured without destroying the structure of EVs. [47] [48] [49] Although EVs are thought to be promising cancer biomarkers, few EV biomarkers have been implemented into clinical practice. As we have mentioned above, the conventional methods of analyzing EVs generally require large quantities of EVs and a large amount of time for their isolation. In 2014, Yoshioka et al. was the first to establish a novel method that might facilitate the clinical utilization of EVs by developing capturing methods. 47 This method, called the ExoScreen assay, can detect circulating EVs in the serum based on an amplified luminescent proximity homogeneous assay using photosensitizer beads and two specific antigens residing on EVs. ExoScreen requires only small samples (at least 5 lL), eliminates the complicated isolation process by directly capturing EVs and works with high-throughput analysis. In that study, they showed that circulating EVs could be used to diagnose colorectal cancer more effectively than conventional tumorassociated antigens, such as carcinoembryonic antigen and carbohydrate antigen 19-9. ExoScreen provides a new liquid biopsy procedure to sensitively and expediently detect disease-specific EV. Within the next decade, to satisfy the requirement for clinical applications, the establishment of further high-throughput methods for the detection of disease specific EVs should be pursued.
As drug delivery tools
Recently, there has been intense interest in the potential of EVs as delivery vehicles. EVs have some ideal characteristics, such as stability in body fluids, few side-effects and tropism to some organs. 12 Therefore, EVs have the potential to stably carry substantial therapeutic cargo, such as siRNAs and miRNAs, to target organs. To date, several articles have reported that administration of EVs can be therapeutic strategies. Alvarez-Erviti et al. modified the surface of EVs derived from murine dendritic cells to allow them to cross the blood-brain barrier and deliver siRNA to the brain in mice. 50 Ohno et al. engineered the surface of EVs to be selectively recognized by epidermal growth factor receptor. They succeeded in delivering miRNAs to epidermal growth factor receptor-expressing breast cancer cells by using these EVs. 51 
As cancer vaccines
The properties of EVs that modulate the immune system illustrate the potential of EVs as a cancer vaccine. The idea to use EVs as cancer vaccines arose from a report published more than 20 years ago. In 1996, Raposo et al. reported that EVs secreted by B lymphocytes stimulate human CD4 + T cells in an antigen-specific major histocompatibility complex class-dependent manner, suggesting a role of EVs for antigen presentation. 52 Two years later, Zitvogel et al. was the first to report that dendritic cellderived EVs, which were referred to as Dex, could present tumor-associated antigens and promote T-cell activation, resulting in the suppression of tumor growth. 53 Since then, the molecular characterization and immunological properties of Dex were further investigated. There are as of yet no reports available using Dex in urological cancers; however, the strategy of loading Dex with tumor antigens has been used in clinical practice as a cell-free cancer vaccine for several kinds of cancers, such as melanoma, and lung and colorectal cancer. 54 Therapeutic strategies for urological cancer using EVs
Although novel strategies, such as molecular targeted therapies, chemotherapies and immunotherapies, have been developed in the past decade, the prognosis for advanced urological cancers remains poor. Further understanding of the pathogenesis in urological cancers is required to overcome this situation. Recently, reports on EVs in urological cancers have emerged. In the next section, we summarize the current reports of EVs in urological cancers and discuss future strategies for cancer treatment conferred by EVs (Tables 1,2 ).
Bladder cancer (BCa)
The diagnosis of BCa is usually based on urinalysis, urine cytology and cystoscopy. Although urine cytology is a highly specific test for the diagnosis of BCa, its sensitivity for the detection of low-grade tumors is limited. 55 In addition, cystoscopy is the gold standard for diagnosis, but this approach is invasive and uncomfortable. Furthermore, even for flexible cystoscopy, the risk of developing a urinary tract infection is approximately 10%. 56 Therefore, reliable and non-invasive biomarkers are required. As BCa is bathed in urine, urine is a suitable fluid that might contain high levels of cancer-associated molecules shed from the BCa. To date, several studies have reported the usefulness of EVs from the urine as a biomarker. On the basis of proteome analysis, Chen et al. proposed that TACSTD2 has diagnostic value as a biomarker for BCa patients. 57 Perez et al. reported the potential application of RNAs, such as LASS2 and GALT1, in urinary EVs for diagnosis. 58 In addition, there have also been several studies on the use of miRNA as a potential biomarker. Matsuzaki et al. reported that miR-21-5p in urinary EVs could be a new biomarker to detect the early stage and negative urine cytology of BCa patients. They carried out microarray analysis of miRNA, which was validated by qRT-PCR. The sensitivity and specificity of miR-21-5p were better than those of urine cytology, and miR-21-5p was also highly expressed in urinary EVs in BCa patients with negative urine cytology. 59 Furthermore, Berrondo et al. recently showed that lncRNAs, such as HOTAIR, HOX-AS-2, ANRIL and linc-RoR, were enriched in urinary EVs derived from BCa patients, suggesting that urinary EVderived lncRNAs have potential as biomarkers for BCa. 60 EVs derived from cancer cells influence surrounding or distant cells by transferring their content. Although >70% of newly diagnosed BCa are non-muscle invasive and the survival rate is high, muscle-invasive BCa has aggressive characteristics and its 5-year survival rate is <50%. 61, 62 Several studies showed that EVs derived from high-grade or invasive BCa promote cancer progression. Beckham et al. reported that EDIL-3 in EVs derived from a high-grade BCa cell line facilitated angiogenesis and the migration of urothelial and endothelial cells. They also showed that the level of EDIL-3 in EVs was significantly higher in the urine of patients with high-grade BCa than in the urine of healthy controls, suggesting its effectiveness as a biomarker for high-grade BCa. 63 Silvers et al. reported that EVs derived from muscle-invasive BCa cells contained a high concentration of periostin and that transfer of periostin in EVs conferred aggressiveness to low- grade BCa cells by activating ERK oncogenic signals. They also found that the presence of periostin in muscle invasive BCa correlated with a worse prognosis. 64 Franzen et al. found that urothelial cells exposed to EVs derived from invasive BCa cell lines or from patients with BCa showed increased expression of several mesenchymal markers and decreased expression of epithelial markers. 65 The authors suggested that the induced changes in urothelial cells make them more at risk to become tumorigenic. 66 Intratumoral hypoxia has been widely accepted as one of the most fundamental aspects of the tumor microenvironment that acts to promote tumor development. 67 Xue et al. reported that hypoxic EVs facilitated BCa growth and development. They found that hypoxic EVs derived from BCa cells contained a higher level of lncRNA-UCA1 than normoxic EVs, and that transfer of lncRNA-UCA1 in EVs could promote cancer progression through the epithelial-mesenchymal transition. 68 Furthermore, EVs can discard tumor suppressive miRNAs during tumor progression as a mechanism to coordinate the activation of a metastatic cascade. Ostenfeld et al. reported that RAB family members, RAB27A or RAB27B, regulated the secretion of tumor-suppressive miRNA, such as miR-23b in EVs, and that EV-mediated secretion of tumor-suppressive miRNA contributed to BCa progression. 69 In contrast, Greco et al. reported the usefulness of EVs as a vector to deliver siRNA in BCa. PLK-1 siRNA was loaded into EVs derived from HEK293 cells and mesenchymal stem cells through electroporation, and transported the siRNA to an invasive BCa cell line (UMUC3) and normal epithelial cells. They found that BCa cells were >50-fold more likely to uptake EVs than normal epithelial cells. In addition, UMUC3 cells treated with EVs containing PLK1 siRNA had reduced expression of PLK1 mRNA, supporting the idea that EVs could deliver siRNA to target cells. 70 
Kidney cancer (RCC)
RCC is a common urological cancer that accounts for 3% of adult cancers and 90-95% of neoplasms arising from the kidney. 71 RCC is clinically silent at its earliest stages, and approximately 30% of patients present with metastasis at the time of diagnosis. 72 Therefore, a means of identifying patients with RCC is greatly required.
Several reports have shown the utility of urinary EVs as an RCC biomarker. Palma et al. reported that the expression levels of GSTA1, CEBPA and PCBD1 in EVs were decreased in the urine of RCC patients compared with healthy controls. 73 In addition, proteomic analysis showed the effectiveness of proteins, such as MMP-9, PODXL, DKK4, CAIX and ceruloplasmin, contained within EVs as biomarkers. 74 Serum EVs have also been reported as a diagnostic tool for RCC. MiR-210, miR-1233 and miR-224 in serum EVs have been detected as diagnostic or prognostic biomarkers for clear cell RCC. 75, 76 Recently, Jingushi et al. reported a method to collect EVs directly from viable human tissue samples. 77 They collected EVs derived from surgically resected viable clear cell RCC tissue and adjacent normal renal tissues through a brief incubation in serum-free medium, and compared them by quantitative liquid chromatography-mass spectrometry analysis. Thus, they identified a permeabilizer for vascular endothelial cells, azurocidin 1, as a new clear cell RCC biomarker.
Renal cell carcinoma produces EVs that educate endothelial cells and promote angiogenesis. Grange et al. reported that CD105
+ RCC stem cells release EVs that trigger angiogenesis and promote the formation of a premetastatic niche. CD105 + EVs significantly enhanced the expression of vascular endothelial growth factor and MMP2 in sorted lung endothelial cells, and MMP9 in total lung tissue. 32 Zhang et al. showed that EVs derived from RCC cells increased tubular structures through upregulation of vascular endothelial growth factor expression in HUVECs. 78 Although molecules that induced angiogenesis were not clearly detected in either study, it was suggested that EVs derived from both cancer stem cells and cancer cells contributed to unfavorable tumor outcomes.
Cytoreductive nephrectomy has been recommended as an essential component for the treatment of metastatic RCC, especially in the cytokine era. 79, 80 However, the exact mechanism underlying the beneficial effect of cytoreductive therapy has not yet been elucidated. Prevalent hypotheses are that it might remove a source of tumor-promoting growth factors or immunosuppressive cytokines. 81 Therefore, the effectiveness of cytoreductive therapy might also be related to the reduction of cancer-derived EV transfer.
During the past decade, a number of targeted therapies have been approved for the treatment of metastatic and advanced RCC. 82 Sunitinib is a first-line targeted drug for metastatic RCC patients. However, its effectiveness does not last for long periods due to resistance. 83 Qu et al. showed that resistance to sunitinib was caused by the transfer of EVs, which can be mediated by an lncRNA named "lncARSR." They found that extracellular lncARSR conferred sunitinib resistance to sensitive cells by competitively binding miR-34/ miR-449, and promoting AXL and MET expression in RCC cells. 84 They suggested the potential of lncARSR as a biomarker and therapeutic target for sunitinib resistance.
Several articles reported that tumor-derived EVs could also be used as a vaccine for RCC. Zhang et al. reported that EVs derived from interleukin-12-anchored renal cancer cells promoted the proliferation of T cells and subsequently increased the release of interferon-c. In addition, the EVs induced CTLs, revealing increased immunogenicity through RCCderived EVs. 85 Gu et al. reported the effectiveness of the vaccination of dendritic cells loaded with EVs derived from RCC. 86 They showed that mice bearing the mouse RCC cell line, RENCA, survived longer when they had been vaccinated with dendritic cells loaded with EVs than when they had been vaccinated with dendritic cells loaded with whole tumor lysate. 86 These studies showed the usefulness of tumor-derived EVs as antigen-delivery carriers in RCC.
Prostate cancer (PCa)
PCa is the second most frequently diagnosed male cancer worldwide. 87 Although prostate-specific antigen measurements have helped to detect early cases of PCa and has changed the clinical management of the disease, it has some limitations. It lacks the specificity to discriminate benign prostate disease, such as benign hyperplasia and infection, and PCa. 88 In addition, this screening is associated with a high risk of overdiagnosis and overtreatment. 89 Therefore, new biomarkers that are more specific for PCa are required to prevent unnecessary prostate biopsies. 90 Because of the anatomical localization of the prostate, urine appears to be an ideal substrate to detect PCa carcinogenesis. Several reports have shown the effectiveness of urinary EVs as diagnostic markers. [91] [92] [93] [94] [95] Recently, McKiernan et al. developed an FDA-approved non-invasive detection test, the ExoDx Prostate IntelliScore urine exosome assay. ExoDx uses a urinary substrate and utilizes a three EV gene assay signature (PCA3, ERG and SPDEF) to construct a score (ExoDx Prostate IntelliScore). They reported that ExoDx was predictive of high-grade PCa (Gleason score ≥7) from low-grade cancers, and reduced the number of potentially unnecessary prostate biopsies. 96 EVs isolated from the plasma have also been shown to contain proteins specific to PCa, such as PTEN and survivin. 97, 98 Although aggressive PCa is associated with a reduction in or loss of PTEN expression, PTEN has been detected only in EVs derived from patients with PCa and not from healthy controls. 97 In addition, a higher EV level of survivin has been shown to be present in patients with PCa than in patients with benign prostatic hyperplasia or healthy controls. 98 MiRNA within serum or plasma EVs has diagnostic and/or prognostic potential for PCa. MiR-141 and miR-375 in serum EVs have been associated with metastatic PCa. 99, 100 In another study, Huang et al. described miR-1290 and miR-375 in plasma EVs as potential prognostic biomarkers for patients with metastatic PCa. 101 They carried out RNA sequencing and confirmed that these miRNAs were significantly associated with poor overall survival in CRPC patients. 101 In the past few years, several new drugs have emerged for the treatment of CRPC patients, such as enzalutamide and abiraterone acetate. Although these drugs represent breakthroughs for the treatment of CRPC, approximately 20-40% of patients have no response to these agents. 102 AR-V7 is associated with resistance to enzalutamide and abiraterone in metastatic CRPC patients, and many researchers are focusing on the possibility of AR-V7 as a biomarker. 102, 103 Recently, Del et al. reported the role of AR-V7 in RNA extracted from plasma-derived EV as a predictive biomarker of resistance to hormonal therapy in metastatic CRPC patients. 104 Bone metastasis is common in advanced PCa; it not only is incurable, but also causes skeletal-related events that devastate one's quality of life. Previous reports showed that EVs derived from PCa cells promote proliferation, 105 modulate the immune system 106 and provide drug resistance, 107 which together support tumor progression. Recently, several articles suggested that intercellular communication through EVs might contribute to the progression of bone metastasis. Although bone metastasis of PCa is mainly thought to be osteoblastic, osteoblastic metastatic lesions are the result of a complex interplay between cancer cells, osteoblasts and osteoclasts. 108 Such a feedback loop among disseminated tumor cells, osteoblasts and osteoclasts is known as a "vicious cycle," which is thought to be a major mechanism for bone metastatic outgrowth. 109 Ito et al. were the first to report the intercellular communication between PCa cells and osteoblasts through EVs. They found that EVs derived from human hormone-refractory PCa cells, DU-145 and PC-3, which contain the Ets-1 protein, induced differentiation of murine MC3T3-E1 pre-osteoblastic cells. 110 Recently, Ye et al. showed that EVs derived from a PCa cell line, MDA PCa 2b, promoted osteoblast activity and regulated the bone metastasis microenvironment. They found that secreted miR-141-3p reduced levels of DLC1 in osteoblasts and activated the p38MAPK pathway, promoting osteoblast proliferation and OPG/RANKL expression. In addition, they also found that EVs derived from PCa had bone-target specificity and promoted osteoblastic bone metastasis in vivo. 111 Karlsson et al. reported that EVs derived from the murine PCa cell line, TRAMP-C1, decreased fusion and differentiation of murine osteoclast precursors to mature multinucleated osteoclasts. Although the molecular mechanism underlying this phenotype was not shown, they suggested that EVs derived from PCa also regulated osteoclast differentiation in bone metastatic sites. 112 The mechanism of bone metastasis is quite complex, and therefore, further studies are required. However, these reports suggest that EVs might provide great benefit in the treatment of patients with bone metastasis.
Future perspectives for clinical applications
In the present review, we summarized current EV studies to discuss the potential of EVs in urological cancer treatment. Here, we provide a perspective on the potential contribution of EV research to the development of urological cancer therapeutics and diagnosis (Fig. 2) .
In therapeutic targets
The inhibition of intercellular communication through EVs could provide an opportunity to suppress tumor progression. In contrast, the transfer of EVs must also modulate normal physiological function. Indeed, the downregulation of nSMase2 was effective for lung metastasis in breast cancer by reducing the amount of EV secretion. 33 However, it has been reported that nSMase2 is expressed in normal neural cells. 113 In addition, the suppression of nSMase2 might not have the same inhibitory effect on EV secretion in all types of cancer. In fact, a similar inhibitory effect was not observed in PCa cells. 114 Therefore, to establish EV target therapy in urological cancer, the identification of urological cancer-specific genes or molecules that are essential for EV communication is required.
In biomarkers
The speed of drug development is astonishing, and the demand to identify an EV biomarker as a proper candidate is increasing. Nivolumab was recently approved as a sequential therapy for advanced and metastatic RCC. In addition, pembrolizumab was also approved for platinum-refractory advanced urothelial cancer. There are PD-1 immune checkpoint inhibitor antibodies that selectively block the interaction between PD-1, which is expressed on the surface of T cells, and PD-L1, which is expressed on immune cells and cancer cells. 115 Direct assessment of PD-L1 expression on tumor cells is a logical biomarker to predict treatment response. However, determining which patients will benefit from PD-1/PD-L1-directed immunotherapy remains an important clinical question. This might be related to the fact that PD-L1 expression is transient, and intrapatient and intratumor heterogeneity in PD-L1 expression exists. 116 EVs are secreted from heterogeneous cancer cells and reflect the current state of the tumor; therefore, EVs have great potential as effective biomarkers. Indeed, Haderk et al. reported that non-coding Y RNA hY4 in EVs derived from chronic lymphocytic leukemia modulate PD-L1 expression in monocytes. 117 In addition, several studies reported that miRNAs regulated the expression of PD-L1. 118, 119 These reports suggest that EVs derived from cancer modulate PD-L1 expression and might influence therapeutic efficacy. Furthermore, Theodoraki et al. recently reported the PD-L1 level on EVs associated with disease progression in neck squamous cell carcinoma. 120 Although they did not show the relationship between the expression level of PD-L1 on EVs and therapeutic effectiveness, EVs could be great predictors in this field.
In drug delivery tools
It has been shown that the loading of siRNA into EVs reduces gene expression in recipient BCa cells, and that the use of EVs as drug delivery carriers has the possibility to be a key step toward the clinical application of drug delivery. 70 However, this technology is still new. First, the efficiency of loading siRNAs into EVs should be improved, because the current efficiency through electroporation is <30%. 121 In addition, several groups recently reported the importance of the identification of EV subpopulations, and a better understanding of the organ/tissue specific tropism of different subpopulations of EVs is required. 122, 123 Furthermore, animal studies are required to verify that siRNA can be effectively delivered to target urological cancer cells in vivo.
In cancer vaccines
In urological cancer, cancer vaccine therapy, such as dendritic cell-based vaccines and personalized peptide vaccines, is attracting attention, and several clinical trials have shown its potential as a new therapeutic candidate. 124 As we have shown above, tumor-derived EVs have a role as tumor antigens and promote an antitumor immune response. 85, 86 However, a number of studies have reported that EVs derived from cancer cells promote cancer development, and it might be difficult to reconcile these two aspects. 10 Another popular strategy for cancer vaccine therapy using EVs is Dex immunotherapy. Until now, three phase I clinical trials and one phase II trial using Dex have been completed in advanced cancer. [125] [126] [127] [128] However, they could only show limited clinical efficacy in advancedstage cancer patients. Although the limited efficacy of Dex immunotherapy could be due to the small, advanced-stage patient cohorts used and the lack of preselection criteria, further research will be required to assess clinical applications.
Conclusion
In the present review, we summarized current EV research to discuss the potential of EVs in urological cancer treatment. EVs play pivotal roles in intercellular communication during urological cancer development. Thus, targeting this communication will provide a new therapeutic strategy. In addition, as EVs are present in various bodily fluids and the cargo of biological molecules reflects the patients' condition, EVs can be used as novel diagnostic or prognostic tools to serve as a non-invasive "liquid biopsy." Furthermore, we might be able to use EVs as drug delivery modules or as cancer vaccines. Further research and development are required for clinical applications, but the clinical utility of EVs is promising and there are endless possibilities in the field of EV research.
We enthusiastically hope that the clinical use of EVs will contribute to urological cancer management and treatment in the near future.
